ACHR/WS Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- —
- P/S (TTM)
- —
- EV/EBITDA
- —
Profitability & growth
- ROE (TTM)
- 0.0%
- Operating margin
- 0.0%
- Revenue growth YoY
- 0.0%
- Dividend yield
- —
- Beta
- —
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
27 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About ACHR-WS
Company profileAchieve Life Sciences, Inc. (Ticker: ACHR-WS) is a clinical-stage biopharmaceutical firm dedicated to revolutionizing smoking cessation and nicotine addiction treatment through its lead therapeutic candidate, cytisine. Tackling a critical public health challenge, Achieve seeks to redefine nicotine replacement strategies by focusing on enhanced efficacy and patient outcomes. The company’s strategic partnerships and active product pipeline development further solidify its role in the rapidly growing health sector, which increasingly demands innovative cessation alternatives. Committed to…
Company profile
- HQ
- NONE
- Latest quarter
- —
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer